反応式
C(OC(=O)[N:7]([C:14]1[C:15]2[N:16]([C:20](Br)=[CH:21][N:22]=2)[CH:17]=[CH:18][N:19]=1)[CH2:8][CH2:9][S:10]([CH3:13])(=[O:12])=[O:11])(C)(C)C.CS[C:27]1[N:32]=[C:31]([Sn](CCCC)(CCCC)CCCC)[CH:30]=[CH:29][N:28]=1.[NH:46]1[CH2:51][CH2:50][O:49][CH2:48][CH2:47]1>>[CH3:13][S:10]([CH2:9][CH2:8][NH:7][C:14]1[C:15]2[N:16]([C:20]([C:31]3[CH:30]=[CH:29][N:28]=[C:27]([N:46]4[CH2:51][CH2:50][O:49][CH2:48][CH2:47]4)[N:32]=3)=[CH:21][N:22]=2)[CH:17]=[CH:18][N:19]=1)(=[O:11])=[O:12]参加物
4
反応物 3
生成物 1
実験手順
(2-Methanesulfonyl-ethyl)-[3-(2-morpholin-4-yl-pyrimidin-4-yl)-imidazo[1,2-a]pyrazin-8-yl]-amine was prepared by a process analogous to that described in Example 12 starting from (3-bromo-imidazo[1,2-a]pyrazin-8-yl)-(2-methanesulfonyl-ethyl)-carbamic acid tert-butyl ester (from Example 5 supra), 2-methylsulfanyl-4-tributylstannanyl-pyrimidine, and morpholine. LC-MS: [M+H]+ 404.2.
出典と根拠
- ORDレコード
- ord-5d4fdea8d9564a2c8ff201151a6c2d67
- 出典データセット
- uspto-grants-2014_03
- 特許番号
- US08673905B2
関連ノート
読み込み中…